Third Strike For Peregrine's Bavituximab

Peregrine Pharmaceuticals is baffled by the recent results of its non-small cell lung cancer trial – a failure they claim was due to a better-than-expected response in the comparator arm. Yet, the failure throws several clinical programs into uncertainty.

The biotech announced after the market close on Feb. 25 that the Phase III SUNRISE trial would be stopped after...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category